Up regulated expression of fractalkine/CX3CL1 and CX 3CR1 in patients with systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 64, Issue 1, 2005, Pages 21-28

  Hasegawa, M ^a   Sato, S ^a   Echigo, T ^a   Hamaguchi, Y ^a   Yasui, M ^a   Takehara, K ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CX3CR1 CHEMOKINE; FRACTALKINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISCHEMIA; LEUKOCYTE ADHERENCE; LUNG FIBROSIS; LUNG PARENCHYMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; SKIN; STATISTICAL ANALYSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ADULT; AGED; CHEMOKINES, CX3C; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PULMONARY FIBROSIS; RECEPTORS, CYTOKINE; RECEPTORS, HIV; SCLERODERMA, SYSTEMIC; SKIN; UP-REGULATION;

EID: 11344287499     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.018705     Document Type: Article

References (43)

1. Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988;18:9-17.
2. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development or scleroderma. J Pathol 1992;166:255-63.
3. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-11.
4. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999;11:503-7.
5. Takehara K. Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol 2003;30:755-9.
6. Roumm AD, Whiteside TL, Medsger TAJ, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
7. Gruschwitz M, Sepp N, Kofler H, Wick G. Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis. Immunobiology 1991;182:234-55.
8. 3C motif. Nature 1997;385:640-4.
9. 3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001;107:1173-81.
10. 3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998;188:1413-19.
11. Umehara H, Bloom E, Okazaki T, Domae N, Imai T. Fractalkine and vascular injury. Trends Immunol 2001;22:602-7.
12. 3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521-30.
13. 3CL1). J Biol Chem 2001;276:37993-8001.
14. Tsou CL, Haskell CA, Charo IF. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 2001;276:44622-6.
15. Kanazawa N, Nakamura T, Tashiro K, Muramatsu M, Morita K, Yoneda K, et al. Fractalkine and macrophage-derived chemokine: T cell-attracting chemokines expressed in T cell area dendritic cells. Eur J Immunol 1999;29:1925-32.
16. + monocytes. J Exp Med 2003;197:1701-7.
17. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997;387:611-17.
18. 3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2878-83.
19. Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001;44:2750-60.
20. 3CR1 rapid communication. Kidney Int 1999;56:612-20.
21. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001;159:1521-30.
22. ARA. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
23. LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
24. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobeser variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
25. Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
26. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 1994;37:391-4.
27. Nagaoka T, Kaburagi Y, Hamaguchi Y, Hasegawa M, Takehara K, Steeber DA, et al. Delayed wound healing in the absence of intercellular adhesion molecule-1 or L-selectin expression. Am J Pathol 2000;157:237-47.
28. Sato S, Miller AS, Inaoki M, Bock CB, Jansen PJ, Tang MLK, et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-dericient mice. Immunity 1996;5:551-62.
29. Furuichi K, Woda T, Iwata Y, Sakai N, Yoshimoto K, Shimizu M, et al. Upregulation of fractalkine in human crescentic glomerulonephritis. Nephron 2001;87:314-20.
30. Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 1992;19:1202-6.
31. Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995;63:48-56.
32. 3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol Cell Biol 2001;79:298-302.
33. Gudbjornsson B, Hallgren R, Nettelbladt O, Gustafsson R, Mattsson A, af Geijerstam E, et al. Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjögren's syndrome. Ann Rheum Dis 1994;53:574-9.
34. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990;88:470-6.
35. Block CM, du Bois RM. Organ involvement: pulmonary. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Baltimore: Williams & Wilkins, 1996:299-332.
36. Matucci-Cerinic M, Kahaleh MB, LeRoy EC. Pathogenesis: vascular involvement. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Baltimore: Williams & Wilkins, 1996:153-74.
37. Kahaleh MB, Fan PS. Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 1997;83:32-40.
38. 3CR1 expression. J Immunol 2002;168:6173-80.
39. Yoneda O, Imai T, Goda S, Inoue H, Yamauchi A, Okazaki T, et al. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 2000;164:4055-62.
40. 3CR1 as a genetic risk factor for coronary artery disease. Blood 2001;97:1925-8.
41. 3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001;89:401-7.
42. -/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003;111:333-40.
43. 3CR1/apolipoprotein E double knockout mice. Circulation 2003;107:1009-16.